Wedbush analyst Laura Chico raised the firm’s price target on Ultragenyx to $47 from $43 and keeps a Neutral rating on the shares. The firm notes the company provided a preannouncement of FY23 results and issued its preliminary FY24 financial guidance targets. Wedbush currently estimates profitability arriving in late-2026, which is also in-line with management’s outlook.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RARE:
- Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
- Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
- Ultragenyx receives positive recommendation from NICE in U.K. for Evkeeza
- Ultragenyx announces completion of enrollment in Phase 1/2 trial of GTX-102
- Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
